Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Copehagen South, Denmark Clinical Trials

A listing of Copehagen South, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (98) clinical trials

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP )

The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients. A drug response predictor (DRP) biomarker in prostate cancer patients will identify patients likely to respond to and benefit ...

Phase

2.25 miles

Learn More »

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Risk has been defined by the International (I) Berlin, Frankfurt, Mnster (BFM) Study Group (SG) based on duration of first remission, ...

Phase

2.25 miles

Learn More »

Intra-oral Treatment of OLP With Rivelin -CLO Patches

Randomized, double-blind, placebo-controlled, parallel group clinical study with 3 active dose arms (Rivelin-CLO patches) and one placebo arm (Rivelin plain patch). Up to 6 Rivelin patches will be applied to symptomatic ulcerative and symptomatic erythematous OLP lesions. After screening (visit 1, day -14 to day -7), patients who have signed ...

Phase

2.25 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

2.25 miles

Learn More »

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Each patient will receive treatment for up to 93 weeks following the first Naxitamab administration and remain in the trial for 101 weeks. After the end of trial visit, each patient will enter a long-term follow-up where they will be monitored for up to 5 years after first treatment cycle. ...

Phase

2.25 miles

Learn More »

Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Phase

2.25 miles

Learn More »

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, ...

Phase

2.25 miles

Learn More »

Study of Nivolumab Plus Ipilimumab Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.

Phase

2.34 miles

Learn More »

Trial in Patients With Relapsed Ovarian Cancer

The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the standard of care (SoC).

Phase

2.34 miles

Learn More »